Acutaas Chemicals Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹437 Cr +42.8% YoYSee revenue, profit and what management said. You are viewing Q1 FY27.
AC

Acutaas Chemicals Ltd

Q1 FY27Pharmaceuticals & Biotechnology

Acutaas Chemicals Q1 FY27 earnings call: Revenue & Margins

Q1 FY27 earnings call: what management said on revenue, margins and capex.

Revenue
₹330Cr
+59.4% YoY
−23.8% QoQ
Net profit
₹75Cr
+70.5% YoY
−44% QoQ
Margin
34%
+9 pp YoY
−8 pp QoQ

What the Q1 FY27 call signalled

2 of 3 strong

RevenueGood growth
MarginMargins steady
CapexCapex planned
Price₹3,265
Market cap₹28.2K Cr
P/E72.9

The short version

The company targets a 25% revenue growth for the full financial year FY '27. Company targets a 25% revenue growth for FY '27, confident to maintain similar EBITDA margins as FY '26 despite higher revenue.

From Acutaas Chemicals Ltd's Q1 FY27 earnings-call transcript · updated 23 Sept 2026.

Revenue & Sales Performance

Good growth
  • The company targets a 25% revenue growth for the full financial year FY '27.
  • Battery chemicals business expected to ramp up to full capacity utilization (4,000 MT) by FY '29, indicating strong volume growth.
  • Semiconductor business (Indichem plant) to start contributing revenues from FY '28 and expected to reach full capacity within 3-4 years.
  • Pharma Intermediates, including CDMO business, expected to grow strongly, with CDMO revenue target of INR 1,000 crores and confident to exceed it.
  • Spec Chem business revenue mix to grow due to battery chemicals and new higher-margin specialty chemicals despite phasing out commodity chemicals.

2 more points from Acutaas Chemicals Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Acutaas Chemicals Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Capex planned
  • FY '27 capex estimated at around INR 90-95 crores, including:
  • Spillover capex of electrolyte additives and pilot plant capex (~INR 50 crores)
  • Maintenance capex of INR 40-45 crores
  • Additional capex planned for a new R&D center and land acquisition for future capacity expansion; details to be announced when finalized.
  • Land acquisition is intended to support capacity expansion for the Pharma Intermediate business as existing plants (Sachin and Ankleshwar) approach full utilization by FY '28.
  • Indichem plant construction is ahead of schedule, with capex completion expected by end of Q1 FY '27; revenue anticipated from next financial year.

2 more points from Acutaas Chemicals Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Acutaas Chemicals Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

Some relevant points regarding business outlook and contracts are noted: - Battery chemical business has active long-term supply contracts for VC and FEC products, with full capacity utilization expected within 3 years. - Third product in battery electrolytes developed, with a long-term supply contract in finalization stage; fourth product planned afterward.

2 more points from Acutaas Chemicals Ltd's call on order book

Create a free account to keep reading this call

Acutaas Chemicals Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Acutaas Chemicals Ltd Q1 FY27 results — key figures

Acutaas Chemicals Ltd Q1 FY27 reported results vs Q1 FY26, ₹ crore
₹ CrQ1 FY27Q1 FY26YoYQ4 FY26QoQ
Revenue330207+59.4%433-23.8%
Operating profit (EBITDA)11351+121.6%184-38.6%
Operating margin34%25%+9 pp42%-8 pp
Profit before tax10458+79.3%184-43.5%
Net profit (PAT)7544+70.5%134-44%
EPS (₹)9.075.41+67.7%16.09-43.6%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹437 Cr, net profit ₹123 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • KRM Ayurveda (Q1 FY27)

    Total income for Q1 FY27: ₹3,286.55 Lakhs, +32.4% YoY . Key investor presentation takeaways from KRM Ayurveda Ltd's Q1 FY27 investor presentation — and how it r

  • Balaxi Pharma (Q1 FY27)

    Q1 FY27 Revenue: ₹80.68 crore, up 14.1% YoY from ₹70.74 crore in Q1 FY26 (Page 20). Key investor presentation takeaways from Balaxi Pharma's Q1 FY27 investor pr

  • Sanjivani Paranteral (Q1 FY27)

    Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Key investor presentation takeaways from Sanjivani

  • Natural Capsules (Q1 FY27)

    Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Acutaas Chemicals Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Acutaas Chemicals Ltd Q1 FY27 results?

The company targets a 25% revenue growth for the full financial year FY '27. Company targets a 25% revenue growth for FY '27, confident to maintain similar EBITDA margins as FY '26 despite higher revenue.

What is Acutaas Chemicals Ltd share price analysis?

Acutaas Chemicals Ltd currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 72.9 with a market cap of ₹28,166 Cr. Investors should review the full earnings analysis for detailed insights.

Is Acutaas Chemicals Ltd planning capital expenditure?

FY '27 capex estimated at around INR 90-95 crores, including: - Spillover capex of electrolyte additives and pilot plant capex (~INR 50 crores) - Maintenance capex of INR 40-45 crores - Additional capex planned for a new R&D center and land acquisition for future capacity expansion; details to be announced when finalized.

Keep Acutaas Chemicals Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.